[go: up one dir, main page]

AU2003232212A1 - Regulation of erythrocyte apoptosis - Google Patents

Regulation of erythrocyte apoptosis

Info

Publication number
AU2003232212A1
AU2003232212A1 AU2003232212A AU2003232212A AU2003232212A1 AU 2003232212 A1 AU2003232212 A1 AU 2003232212A1 AU 2003232212 A AU2003232212 A AU 2003232212A AU 2003232212 A AU2003232212 A AU 2003232212A AU 2003232212 A1 AU2003232212 A1 AU 2003232212A1
Authority
AU
Australia
Prior art keywords
regulation
erythrocyte
apoptosis
erythrocyte apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003232212A
Other languages
English (en)
Other versions
AU2003232212A8 (en
Inventor
Stephan Huber
Florian Lang
Karl Lang
Philip Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2003232212A8 publication Critical patent/AU2003232212A8/xx
Publication of AU2003232212A1 publication Critical patent/AU2003232212A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003232212A 2002-04-26 2003-04-28 Regulation of erythrocyte apoptosis Abandoned AU2003232212A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10219545.5 2002-04-26
DE10219545A DE10219545A1 (de) 2002-04-26 2002-04-26 Regulation der Apoptose
PCT/EP2003/004390 WO2003090665A2 (fr) 2002-04-26 2003-04-28 Regulation de l'apoptose

Publications (2)

Publication Number Publication Date
AU2003232212A8 AU2003232212A8 (en) 2003-11-10
AU2003232212A1 true AU2003232212A1 (en) 2003-11-10

Family

ID=28798961

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003232212A Abandoned AU2003232212A1 (en) 2002-04-26 2003-04-28 Regulation of erythrocyte apoptosis

Country Status (4)

Country Link
EP (1) EP1530473A2 (fr)
AU (1) AU2003232212A1 (fr)
DE (1) DE10219545A1 (fr)
WO (1) WO2003090665A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10363263B2 (en) 2015-11-04 2019-07-30 Prescient Pharma, Llc Anti-aging compositions and methods for using same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB611518A (en) * 1945-11-20 1948-11-01 Lilly Co Eli Manufacture of quinacrine
US4965251A (en) * 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
EP0310410A3 (fr) * 1987-10-02 1990-01-17 Kawate, Tsuneyoshi Contrôle du flux du potassium activé par le calcium de cellules endommagées du corps
GB9111885D0 (en) * 1991-06-03 1991-07-24 Erba Carlo Spa Nerve growth factor for use in the prevention and treatment of viral infections
US5451600A (en) * 1994-04-19 1995-09-19 Hoffmann-La Roche Inc. Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors
DE4421536A1 (de) * 1994-06-20 1995-12-21 Hoechst Ag Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6221669B1 (en) * 1994-10-19 2001-04-24 Lifecell Corporation Prolonged preservation of blood platelets
NZ298145A (en) * 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
ATE255903T1 (de) * 1995-11-07 2003-12-15 Genentech Inc Stabilisierende formulierung für ngf
WO1999011291A1 (fr) * 1997-09-04 1999-03-11 The Trustees Of The University Of Pennsylvania Procede d'induction de l'apoptose sur les cellules d'une tumeur cerebrale humaine au moyen du facteur de croissance nerveuse
DE69825137T2 (de) * 1998-02-23 2005-07-21 Cilag Ag International Liposomale Erythropoietin-Dispersion
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
WO1999061039A2 (fr) * 1998-05-22 1999-12-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouvelle composition de modulation de la mort cellulaire ischemique
US6355410B1 (en) * 1998-06-03 2002-03-12 Ivan N Rich Method of reducing cell proliferation by inhibiting the Na+/H+ exchanger and inducing apoptosis
GB9817660D0 (en) * 1998-08-13 1998-10-07 Angeletti P Ist Richerche Bio Adenoviral vectors encoding erythropoietin and their use in gene therapy
US6214824B1 (en) * 1998-09-16 2001-04-10 Douglas M. Evans Use of amiloride for treating cancer
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US20030206927A1 (en) * 2000-06-01 2003-11-06 Vesper Stephen Joseph Methods for isolating and using fungal hemolysins
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
DE60213633T2 (de) * 2001-09-14 2007-11-08 ARIZONA BOARD OF REGENTS, on behalf of THE UNIVERSITY OF ARIZONA, Tucson Wortmanninanaloge und verfahren zu deren verwendung
CA2476538C (fr) * 2002-01-09 2012-07-17 Crucell Holland B.V. Utilisation de l'erythropoietine pour le traitement preventif ou curatif de l'insuffisance cardiaque

Also Published As

Publication number Publication date
WO2003090665A3 (fr) 2004-01-08
WO2003090665A2 (fr) 2003-11-06
AU2003232212A8 (en) 2003-11-10
DE10219545A1 (de) 2003-11-06
EP1530473A2 (fr) 2005-05-18

Similar Documents

Publication Publication Date Title
AU2003250690A1 (en) Auto-characterization of optical devices
AU2003202924A1 (en) Variation of neural-stimulation parameters
AU2003236991A1 (en) Representations of processes
AU2002367771A1 (en) Orthodontic separators
AU2003294479A1 (en) Modulation of cytokine-inducible kinase expression
AU2003225088A1 (en) Regulation of tnf-alpha
AU2003262794A1 (en) Total synthesis of heparin
AU2003255787A1 (en) Modulation of immune function
AU2003275505A1 (en) Electowinning of metals
AU2003269268A1 (en) Modulation of immune function
AU2003295790A1 (en) Modulation of iap-like expression
AU2003216663A1 (en) Luminaire
AU2003290763A1 (en) Modulation of jumonji expression
AU2003232212A1 (en) Regulation of erythrocyte apoptosis
AU2003250329A1 (en) Regulation of novel human asparagine-hydroxylases
AU2003218718A1 (en) Utilization of ubiquinones for influencing the effect of histamine
AU2003255810A1 (en) Construction of lampshades
AU2003238034A1 (en) Novel use of imidazotriazinones
AU2003248597A1 (en) The purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
AU2003240688A1 (en) Regulation of human kinase
AU2003270295A1 (en) MANUFACTURE OF Alpha-TOCOPHEROL
AU2003217354A1 (en) Synthesis of sulfamidates
AU2003240450A1 (en) Manufacture of ketopantolactone
AU2003215354A1 (en) Refinement of isointensity surfaces
AU2003217693A1 (en) Beta chain-associated regulator of apoptosis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase